Show simple item record

dc.creatorMartits-Chalangari, Katalin
dc.creatorSpak, Cedric W.
dc.creatorAskar, Medhat
dc.creatorKillian, Aaron
dc.creatorFisher, Tammy L.
dc.creatorAtillasoy, Ercem
dc.creatorMarshall, William L.
dc.creatorMcNeel, David
dc.creatorMiller, Michael D.
dc.creatorMathai, Susan K.
dc.creatorGottlieb, Robert L.
dc.date.accessioned2022-01-26T14:35:08Z
dc.date.available2022-01-26T14:35:08Z
dc.date.issued2021
dc.identifier.urihttps://doi.org/10.1111/ajt.16927
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/ajt.16927
dc.identifier.urihttps://repository.tcu.edu/handle/116099117/49912
dc.description.abstractAn unvaccinated adult male heart transplant recipient patient with recalcitrant COVID-19 due to SARS-CoV-2 delta variant with rising nasopharyngeal quantitative viral load was successfully treated with ALVR109, an off-the-shelf SARS-CoV-2-specific T cell therapy. Background immunosuppression included 0.1 mg/kg prednisone, tacrolimus, and mycophenolate mofetil 1 gm twice daily for historical antibody-mediated rejection. Prior therapies included remdesivir, corticosteroids, and tocilizumab, with requirement for high-flow nasal oxygen. Lack of clinical improvement and acutely rising nasopharyngeal viral RNA more than 3 weeks into illness prompted the request of ALVR109 through an emergency IND. The day following the first ALVR109 infusion, the patient's nasopharyngeal SARS-CoV-2 RNA declined from 7.43 to 5.02 log(10) RNA copies/ml. On post-infusion day 4, the patient transitioned to low-flow oxygen. Two subsequent infusions of ALVR109 were administered 10 and 26 days after the first; nasopharyngeal SARS-CoV-2 RNA became undetectable on Day 11, and he was discharged the following day on low-flow oxygen 5 weeks after the initial diagnosis of COVID-19. The clinical and virologic improvements observed in this patient following administration of ALVR109 suggest a potential benefit that warrants further exploration in clinical trials.
dc.language.isoenen_US
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceAmerican Journal of Transplantation
dc.subjectantibiotic: antiviral
dc.subjectclinical research/practice
dc.subjectheart transplantation/cardiology
dc.subjectimmunobiology
dc.subjectinfection and infectious agents-viral: SARS-CoV-2/COVID-19
dc.subjectinfectious disease
dc.titleALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report
dc.typeArticle
dc.rights.holderThe authors
dc.rights.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/
local.collegeBurnett School of Medicine
local.departmentBurnett School of Medicine
local.personsGottleib (SOM)


Files in this item

Thumbnail
This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/